Immunology

La Trobe University researchers say dying cells can leave behind a residue containing newly identified extracellular vesicles that help direct immune clearance, but laboratory experiments suggest influenza viruses may also use the vesicles to help spread.

4 июня 2026 Сообщено ИИ Проверено фактами

Cancer cells that reduce MHC class I—a common way to evade CD8+ “killer” T cells—may become more vulnerable to destruction by CD4+ “helper” T cells through ferroptosis, according to research led by Baylor College of Medicine and collaborators at the University of Michigan and published in Nature Immunology.

Researchers have developed a genomic mapping technique that reveals how thousands of genes work together to influence disease risk, helping to bridge gaps left by traditional genetic studies. The approach, described in a Nature paper led by Gladstone Institutes and Stanford University scientists, combines large-scale cell experiments with population genetics data to highlight promising targets for future therapies and deepen understanding of conditions such as blood disorders and immune-mediated diseases.

15 декабря 2025 Сообщено ИИ

Researchers at Zhejiang University have developed a novel method to reprogram mast cells, typically involved in allergies, to deliver cancer-fighting viruses directly to tumors. This approach, detailed in a recent Cell journal study, enhances immune responses and shows promise in animal models. It paves the way for personalized cancer therapies.

A new study reveals that breastfeeding leads to a long-term surge in specialized immune cells in breast tissue, potentially reducing cancer risk. Researchers found these CD8+ T cells persist for decades, acting as guards against malignant cells. The findings suggest breastfeeding could enhance natural protection against aggressive breast cancers.

16 октября 2025 Сообщено ИИ

Scientists have developed mRNA vaccines that produce virus-like nanoparticles inside cells, potentially offering more robust immune responses than current versions. In mouse studies, this approach generated antibody levels up to 28 times higher than standard mRNA vaccines. The innovation could reduce side effects by allowing lower doses while maintaining efficacy.